Does neurokinin-1-receptor antagonist aprepitant diminish the efficacy of cyclophosphamide-based chemotherapy?

Sao Paulo Med J. 2009 Nov;127(6):385-6. doi: 10.1590/s1516-31802009000600013.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antiemetics / adverse effects*
  • Antiemetics / therapeutic use
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Aprepitant
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / ethnology
  • Breast Neoplasms / metabolism
  • Cyclophosphamide / analogs & derivatives
  • Cyclophosphamide / metabolism
  • Cyclophosphamide / therapeutic use*
  • Drug Interactions
  • Female
  • Humans
  • Morpholines / adverse effects*
  • Morpholines / therapeutic use
  • Neurokinin-1 Receptor Antagonists*

Substances

  • Antiemetics
  • Antineoplastic Agents, Alkylating
  • Morpholines
  • Neurokinin-1 Receptor Antagonists
  • Aprepitant
  • 4-hydroxycyclophosphamide
  • Cyclophosphamide